Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study†
Nicola Tamburini(Arcispedale Sant'Anna), Giorgio Cavallesco(Arcispedale Sant'Anna), Antonio Stefanelli(Radiation Oncology Associates), Elisa Maietti(University of Bologna), Alessandra Santini, Sara Mazzara(Arcispedale Sant'Anna), Riccardo Righi(Arcispedale Sant'Anna), Pio Maniscalco(Arcispedale Sant'Anna), Rosa Rinaldi(Azienda Ospedaliera Carlo Poma), Nunzio Calia(Arcispedale Sant'Anna), Ivan Santi, Stefania Pedrazzi(Arcispedale Sant'Anna), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Fares Nigim(Harvard University)
Cited by 48
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy
|Cancer Research|2010|244
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240